Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

Abstract

This is the first report of IL-10 antagonist administration to humans. The study shows the involvement of IL-10 in the pathogenesis of SLE, and indicates that the use of IL-10 antagonists may be beneficial in the management of refractory SLE.